

# Discrete-PEG® Technology for Precise and Reproducible Conjugation

## Introduction

Advances in discrete polyethylene glycol (dPEG) conjugation technology, discrete PEG crosslinkers, and monodisperse PEG crosslinkers have enabled more precise control in antibody-drug conjugates (ADC), peptide conjugates, nanoparticles, and imaging probes.<sup>1</sup> These developments support precision bioconjugation reagents used in therapeutic and diagnostic workflows, where consistency and molecular definition are essential.<sup>1</sup> Polyethylene glycol (PEG) is a key component in bioconjugation and drug formulation, offering biocompatibility, solubility, and epitope shielding to enhance stability, reduce degradation, extend circulation, and lower immunogenicity of therapeutic molecules.<sup>2</sup> While conventional PEGs offer beneficial biocompatibility and solubility, their broad molecular weight distribution limits design precision. Despite the utility of conventional PEGs, several challenges persist that limit their effectiveness in bioconjugation.<sup>3</sup> Additionally, polydispersity and hydrophobicity can contribute to aggregation and have been linked to immunogenic responses, including anti-PEG antibody formation.<sup>4</sup>

Vector Laboratories' proprietary dPEG® (discrete PEG) technology addresses these fundamental limitations by providing single-molecular weight, highly pure, precision engineered PEG linkers with exact chain lengths and

orthogonal functional groups.<sup>5,6</sup> dPEG®s feature exact chain lengths (such as dPEG4, dPEG12, and dPEG24) with functional groups that include NHS esters, maleimides, azides, carboxylic acids, and amines. These structures enable reproducible and analytically clear bioconjugation for therapeutic and diagnostic applications.<sup>7</sup> Their controlled synthesis produces consistent homogeneity from 200 Da to 16 kDa, supporting predictable pharmacokinetics and biodistribution. In addition, branched structures can be constructed from three to nine of the linear chains. Discrete PEG reagents have been reported to contain reactive groups, fluorescent probes, metal chelates, drug molecules, affinity ligands, biotin, and many other components. These factors highlight the value of discrete dPEG® linkers as a next generation solution for precise and reproducible bioconjugation.


## dPEG® Technology Overview

dPEG® technology represents a paradigm shift from conventional PEG polymers by introducing molecular precision and design flexibility. The advantages of discrete dPEG® linkers over traditional PEG polymers are summarized in **Table 1**, including improvements in molecular uniformity, design flexibility, and analytical simplicity.

**Table 1: Key Advantages of dPEG® over Conventional PEGs**

Feature	Conventional PEG	dPEG®
Molecular Uniformity	Polydisperse mixtures with broad molecular weight distribution	Monodisperse, single-molecular-weight compounds
Conjugate heterogeneity	Conjugated products will have a distribution of chain lengths	Conjugates are uniform (same cross-linker in each molecule)
Design flexibility	Restricted spatial and functional control	Fully designable linker length and functional end groups
Analytical Characterization	Complex due to heterogeneity	Simplified and precise due to defined structure
Reproducibility	Batch-to-batch variability	High reproducibility and consistency
Pharmacokinetics Control	Limited due to variable chain lengths	Predictable and tunable pharmacokinetics
Immunogenicity Risk	Higher, especially with high-MW PEGs	Lower, especially with short, discrete PEGs
Applications	General PEGylation, limited in precision-demanding systems	ADCs, peptide conjugates, diagnostics, targeted delivery systems

**Figure 1** illustrates the contrast between polydisperse PEG polymers and monodisperse dPEG® crosslinkers, highlighting the single molecular weight precision achieved through controlled synthesis.



**Figure 1.** Side by side mass spectra comparing a polydisperse PEG1000 sample ( $M_w = 1027$ ,  $M_n = 888$ ,  $\mathcal{D} = 1.16$ ; mass ranges between 600–1500 Daltons) with the monodisperse dPEG®24 reagent QBD 10317 ( $M_w = 1146.355$  Da;  $\mathcal{D} = 1$ ), showing the shift from dispersed to single molecular weight species.

Vector Labs' BioDesign™ portfolio includes multiple architectural classes tailored to therapeutic and diagnostic needs:

**Controlled Architecture:** Precise linear, branched, and orthogonal dPEG® architectures.

**Customizable Reactivity:** Broad range of reactive groups for flexible conjugation.

**Enhanced Hydrophilicity:** Superhydrophilic™ spacers for improved solubility and low aggregation.

**Analytical Clarity:** Defined, monodisperse structures for clean analytics and reproducibility.

The product catalog spans a broad range of applications, including branched dPEG® crosslinkers for high DAR ADCs, Fmoc and *t*-Boc protected dPEG® acids for peptide synthesis, azido, alkyne, and DBCO formats for click chemistry, dPEG® spaced dyes and chelators for enhanced imaging, and amine or carboxy dPEG® reagents for nanoparticle passivation and reduced nonspecific binding.

dPEG® crosslinkers combine small molecule precision with polymer versatility, enabling rational design in therapeutics, diagnostics, and controlled release systems. With reactive groups such as NHS, maleimide, azide, alkyne, PFP, TFP, haloacetyl, and tetrazine, they support click chemistry, bioorthogonal labeling, enzymatic ligation, and site specific conjugation. Their defined architecture improves solubility, reduces aggregation, lowers immunogenicity risk, and delivers reliable bioconjugation performance.

## Application Spectrum of dPEG® Technology

The development of dPEG® crosslinkers has broadened the applicability of PEG chemistry across multiple domains of biotechnology, diagnostics, and therapeutic formulation.

Their precise structure, modular chemistry, and high hydrophilicity enable reproducible, high-performance conjugations across diverse molecular systems, from peptides and antibodies to nanoparticles and fluorescent dyes. Each listed application leverages the precise architecture and monodispersity of dPEG®, providing clear benefits over traditional heterogeneous PEGs.

## Drug Delivery: Liposomes and Nanocarriers

dPEG® crosslinkers are widely used in the formulation of liposome-based drug delivery systems and advanced nanocarriers to address challenges related to solubility, aggregation, and pharmacokinetics.<sup>8</sup> Their Superhydrophilic™, monodisperse architecture modulates drug release rates and enhances stability by providing a consistent hydrophilic shell, which reduces opsonization and immune clearance. This controlled surface modification translates into improved bioavailability and longer systemic circulation for encapsulated or conjugated therapeutics, thereby increasing therapeutic efficacy and reducing off-target toxicity.

## Serum Half-Life Extension (PEGylation)

Branched and multi-arm dPEG®s serve as molecular spacers and shielders in PEGylation, significantly enhancing the serum half-life of proteins, peptides, and antibody fragments. Unlike traditional polydisperse PEG, discrete PEG architectures prevent batch-to-batch variability and immunogenicity, delivering reproducible pharmacokinetic profiles.<sup>9</sup> Clinical evidence shows dPEGylated biotherapeutics resist proteolytic degradation and renal clearance, ensuring sustained therapeutic action for protein drugs, enzymes, and fragments while reducing the risk of anti-PEG antibody formation.

## Crosslinkers for IVD/Clinical Conjugates

dPEG<sup>®</sup> crosslinkers provide versatile architectures for conjugating biomolecules in *in vitro* diagnostics and clinical assays. Their hydrophilic nature reduces nonspecific binding and aggregation, improving assay sensitivity and reproducibility. These linkers are widely used in ELISA kits, biosensors, and immunoassays where precise molecular spacing and stability are critical for accurate detection.<sup>10</sup> Amino-dPEG36-<sup>t</sup>Bu ester was used as a cross-linker in creating well-defined, water-soluble C60-PEG conjugates, which exhibit thermo-responsive properties.<sup>11</sup>

## Fluorescent Labels & Imaging

The application of Superhydrophilic™ dPEG<sup>®</sup> compounds in fluorescent labels and imaging is transforming antibody and protein labeling. Traditional fluorescent dyes often exhibit high hydrophobicity, leading to antibody instability and increased nonspecific background in assays. In contrast, dPEG<sup>®</sup> modified fluorescent dyes enhance water solubility and biocompatibility, allowing for more effective labeling without compromising antibody integrity.<sup>12</sup> This innovation results in brighter dyes with improved specificity towards targets, enabling greater fluorescence intensity and reducing nonspecific binding in detection applications. Short dPEG<sup>®</sup> crosslinkers (dPEG4, dPEG8) have been found to improve the performance of antibody-indocyanine green (ICG) optical imaging probes by increasing covalent binding and stability, reducing non-specific background, and enabling higher tumor-to-background imaging ratios *in vivo*.<sup>13</sup>

## Click Chemistry Reagents

dPEG<sup>®</sup> click reagents, including azides, alkynes, and DBCO derivatives, enable bioorthogonal conjugation under mild conditions. Their molecular precision ensures predictable reaction kinetics, consistent product profiles, and low immunogenicity.<sup>14</sup> Metal-free (strain promoted or copper-free) click ready dPEG<sup>®</sup>s are particularly valuable for labelling sensitive biomolecules, proteins, or nucleic acids without risking cytotoxic residues.<sup>15</sup> Their hydrophilic nature ensures compatibility with aqueous environments, making them ideal for biomedical and nanotechnology applications.

## Surface Modifiers

dPEG<sup>®</sup> crosslinkers and passivators are employed to modify nanoparticles, beads, and sensor surfaces, imparting non-fouling, hydrophilic coatings that greatly suppress nonspecific protein adsorption and cellular uptake.<sup>12</sup> Gold and magnetic particles coated with dPEG<sup>®</sup> exhibit higher targeting specificity and lower “background,” enabling precise biosensing, targeted imaging, and selective cell capture. In addition, dPEG<sup>®</sup> passivators prolong nanoparticle circulation and stability, critical for diagnostic imaging and drug delivery applications, and help prevent aggregation and opsonization *in vivo*.

## Peptide Building Blocks and Scaffold Assembly

dPEG<sup>®</sup> serves as a modular scaffold for solid-phase peptide synthesis, enabling the creation of Fmoc, *t*-boc, thiol, and other crosslinker functionalized building blocks. This flexibility is used to design tailored probes, enzyme substrates, and biotherapeutic conjugates with precise length, hydrophilicity, and reactivity. The resultant constructs feature predictable pharmacokinetic and biological activity, and applications span cancer targeting, enzyme therapy, and imaging agent preparation. Studies have shown building a modular scaffold using discrete-length PEGs for PIE12-trimer synthesis, enabling multimeric D-peptide conjugates with enhanced potency, membrane targeting, and strong resistance to HIV mutations.<sup>16</sup>

## ADC Linker Reagents

ADCs benefit from dPEG<sup>®</sup> crosslinkers that enhance solubility and reduce aggregation of hydrophobic payloads. These crosslinkers improve pharmacokinetics and therapeutic index by ensuring controlled drug release and minimizing off-target toxicity. dPEG<sup>®</sup> technology is pivotal in next-generation ADC development for oncology.<sup>6</sup> Recent study highlights the role of dPEG<sup>®</sup> based crosslinkers in ADCs, demonstrating how they provide steric shielding that modulates enzyme-mediated payload release, ultimately enhancing selectivity and stability.<sup>17</sup>

The dPEG<sup>®</sup> application spectrum is illustrated in the table below, linking product types to practical applications.

**Table 2. dPEG<sup>®</sup> Types and Their Specific Application Areas**

Application Area	dPEG <sup>®</sup> Type
Fluorescent Dye and Probe Labeling	AQuora <sup>®</sup> dyes with dPEG spacers <sup>18-21</sup>
Solid-Phase Peptide Synthesis (SPPS)	dPEG4, dPEG8 <sup>16</sup>
Antibody-Drug Conjugates (ADCs)	dPEG8, dPEG12, dPEG24 <sup>17,22-24</sup>
Peptide and Protein Conjugation	Azido-dPEG12-acid, dPEG4, dPEG8 <sup>25</sup>
Controlled-Release Formulations	dPEG spacers in polymer-drug matrices <sup>5, 18, 26</sup>
Enzyme Stabilization and Surface Coating	Carboxy-dPEG12-NHS ester <sup>27, 28</sup>
Nanocarrier Surface Modification	Amino-dPEG24-acid <sup>29</sup>

## Find the Right dPEG® for Your Research Application

dPEG® reagents represent a significant advancement over conventional PEG polymers, offering monodisperse, precisely defined molecular weights and chain lengths. These features provide superior control in bioconjugation, peptide synthesis, drug delivery, and diagnostic applications. Choosing the appropriate dPEG® reactive functional group is critical for optimizing conjugation efficiency, stability, and specificity in your research. The following table correlates common dPEG® reactive end groups with key application areas:

**Table 3. Optimizing dPEG® Selection: Reactive Groups and Their Key Applications**

Reactive dPEG® Group	Biomolecule Target	Typical Conjugation Chemistry	Ideal Application Areas
NHS Esters (N-Hydroxysuccinimide esters)	Primary amines (-NH <sub>2</sub> )	Amide bond formation with amines	Peptide and protein conjugation, antibody-drug conjugates (ADCs), nanoparticle surface modification for improved targeting and stability, fluorescent labeling
Maleimides	Thiol groups (-SH)	Michael addition to cysteine thiols	Site-specific peptide and protein conjugation, ADC linker reagents, fluorescent probe labeling
Azides	Alkynes in click chemistry	Copper- or copper-free click conjugation	Bioorthogonal reactions for peptide conjugation, controlled release drug formulations, fluorescent and imaging probes, oligonucleotide modifications
Alkynes	Azides in click chemistry	Copper- or copper-free click conjugation	Bioorthogonal labeling in sensitive biological systems, peptide and protein modification, advanced diagnostics
Carboxylic acids	Primary amines (-NH <sub>2</sub> ) via carbodiimide coupling	Amide bond formation via EDC/NHS coupling	Surface modification of nanoparticles, enzyme stabilization coatings, peptide synthesis scaffolds
Amines	Carboxylic acids	Amide bond formation	Controlled polymer conjugation, peptide modification, nanoparticle functionalization
Hydrazides/Alkoxyamines	Aldehydes (-CHO)	Hydrazone or oxime ligation	Vaccine and immunogen design, controlled release drug formulations, targeted diagnostics
Pyridyl Disulfides	Thiol groups (-SH)	Disulfide exchange	Reversible peptide or protein conjugation, fluorescent labeling, antibody modification
Haloacetyl	Thiol groups (-SH)	Alkylation of cysteine residues	Specific protein conjugation, surface modification
Vinylsulfone/Iodoacetyl	Thiol groups (-SH)	Michael addition or alkylation	Site-specific protein conjugation, ADC development

Selection of dPEG® reagents based on this table will enhance experimental reproducibility, specificity, and success in diverse bioconjugation and biomedical applications.

Beyond selecting the right reactive group, choosing the appropriate crosslinker architecture, linear or branched, has a direct impact on ADC developability, stability, solubility, and *in vivo* performance. **Table 4** summarizes how these crosslinker types address common challenges encountered during ADC design.

**Table 4. Crosslinker Types and Their Impact on Bioconjugate Development Challenges**

Linker Type	Linker-Payload Solubility	ADC Aggregation	Low drug carrying capacity	Inv-DAR/Efficacy Relationship	Rapid Clearance	Systematic Instability	Low Drug Delivery to Tumor Site	High-Drug Delivery to Healthy Tissues
Linear								
Branched								



To further support linker selection, **Table 5** compares the key features, benefits, and limitations of linear versus branched dPEG® crosslinkers. This comparison helps researchers determine the most suitable architecture for payload class, desired DAR, stability, and performance requirements.

**Table 5. Optimizing dPEG® Selection: Reactive Groups and Their Key Applications**

Linker Type	Main Features & Benefits	Limitations
Linear	Hydrophilic spacer improves solubility and increases overall hydrophilicity.	Best for low DAR and/or “non problematic” payloads.
Branched	Can conjugate multiple payloads at conjugation sites. Shown to improve efficacy at payload matched dosing relative to single payloads at more conjugation sites.	Appears to be limited to lower DAR since payloads are “exposed” at the terminus of each branch.

## Outlook for dPEG® Technologies

dPEG® technology is poised to become a cornerstone in next-generation bioconjugation and drug delivery systems. As the demand for precision-engineered linkers grows, dPEG® offers unique advantages that align with emerging trends in biologics, diagnostics, and advanced therapeutics.

## Expansion in ADCs and Targeted Therapeutics

The increasing complexity of ADCs and targeted biologics requires crosslinkers that deliver reproducibility, tunable pharmacokinetics, and improved stability. dPEG® architectures, particularly branched and orthogonal designs will enable higher drug-to-antibody ratios without compromising solubility or increasing aggregation, paving the way for safer, more potent ADCs.<sup>30</sup>

## Integration into Peptide and Oligonucleotide Platforms

Peptide-based drugs and oligonucleotide conjugates face challenges of poor solubility and aggregation. Short dPEG® spacers will play a critical role in improving synthesis yields, reducing steric hindrance, and enhancing bioavailability, supporting the growth of peptide therapeutics and RNA-based modalities.<sup>31</sup> Several studies have demonstrated altered biodistribution of antibodies or antibody fragments, such as the Fab' fragment (F9) of A5B7 and mCC49 Fab' after PEG modification, resulting in increased tumor accumulation and reduced levels in normal tissues.<sup>32</sup>

## Vaccine and Immunogen Design

Liposomes modified with dPEG® crosslinkers create highly stable and hydrophilic delivery vehicles suitable for encapsulating advanced vaccine modalities (such as mRNA, recombinant proteins, DNA, and cell lysates). Incorporating dPEG® into hapten-carrier conjugates significantly enhances the immune response to the bound antigen or hapten, without triggering immunogenicity toward the linker, an advantage not seen with hydrophobic crosslinkers. This approach is expected to support next-generation vaccines, including mRNA and protein-based platforms.<sup>33, 34</sup>

## Advanced Diagnostics and Imaging

Hydrophilic dPEG® modified dyes, such as AQuora®, already demonstrate superior performance in multiplex imaging and immunostaining. Future developments will extend into PET tracers, real-time *in vivo* diagnostics, and nanoparticle-based assays, leveraging dPEG® chemistry for enhanced signal clarity and reduced nonspecific binding.<sup>5</sup>

## Addressing PEG Immunogenicity

Reports of anti-PEG antibodies primarily involve high-molecular-weight polymeric PEGs. dPEG®'s discrete, low molecular weight architecture significantly reduces immunogenic risk, positioning it as a safer alternative for long-term therapeutic use.<sup>35, 36</sup>

## Conclusions

dPEG® crosslinkers deliver a level of precision, consistency, and design flexibility that conventional PEGs cannot provide. Their monodisperse architecture supports predictable bioconjugation outcomes, improved solubility, reduced aggregation, and clearer analytical characterization. These advantages are essential for ADC development, peptide and protein conjugation, advanced imaging, nanoparticle engineering, and next generation therapeutic design. As bioconjugation workflows increasingly require reproducibility and molecular control, dPEG® technology offers a reliable and high performance platform that enables robust, scalable, and future ready biologics and diagnostic applications.

**Click here** to explore our full range of dPEG® products for your applications.

## References

1. Su, Z.; Xiao, D.; Xie, F.; Liu, L.; Wang, Y.; Fan, S.; Zhou, X.; Li, S. Antibody-Drug Conjugates: Recent Advances in Linker Chemistry. *Acta Pharmaceutica Sinica B* 2021, 11 (12), 3889–3907. <https://doi.org/10.1016/j.apsb.2021.03.042>.
2. D'souza, A. A.; Shegokar, R. Polyethylene Glycol (PEG): A Versatile Polymer for Pharmaceutical Applications. *Expert Opinion on Drug Delivery* 2016, 13 (9), 1257–1275. <https://doi.org/10.1080/17425247.2016.1182485>.
3. Bento, C.; Katz, M.; Carlos, M. Striving for Uniformity: A Review on Advances and Challenges to Achieve Uniform Polyethylene Glycol. *Organic Process Research & Development* 2024, 28 (4), 860–890. <https://doi.org/10.1021/acs.oprd.3c00428>.
4. Fu, S.; Zhu, X.; Huang, F.; Chen, X. Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. *Pharmaceutics* 2025, 17 (8), 1074. <https://doi.org/10.3390/pharmaceutics17081074>.
5. Hu, J.; Liu, S. Emerging Trends of Discrete Poly(Ethylene Glycol) in Biomedical Applications. *Current Opinion in Biomedical Engineering* 2022, 24, 100419. <https://doi.org/10.1016/j.cobme.2022.100419>.
6. Cen, J.; Hou, M.; Liu, S. Discrete Polyethylene Glycol Derivatives as a Potent Impetus for Next-Generation Biomedicines. *Giant* 2023, 15, 100169–100169. <https://doi.org/10.1016/j.giant.2023.100169>.
7. What Is DPEG®? | Vector Labs. VectorLabs. <https://vectorlabs.com/what-is-dpeg/> (accessed 2025-11-26).
8. Povoski, S. P.; Davis, P. D.; Colcher, D.; Martin Jr, E. W. Single Molecular Weight Discrete PEG Compounds: Emerging Roles in Molecular Diagnostics, Imaging and Therapeutics. *Expert Review of Molecular Diagnostics* 2013, 13 (4), 315–319. <https://doi.org/10.1586/erm.13.19>.
9. Burke, P. J.; Hamilton, J. Z.; Jeffrey, S. C.; Hunter, J. H.; Doronina, S. O.; Okeley, N. M.; Miyamoto, J. B.; Anderson, M. E.; Stone, I. J.; Ulrich, M. L.; Simmons, J. K.; McKinney, E. E.; Senter, P. D.; Lyon, R. P. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates. *Molecular cancer therapeutics* 2017, 16 (1), 116–123. <https://doi.org/10.1158/1535-7163.mct-16-0343>.
10. Hermanson, G. T. *Bioconjugate Techniques*; Acad. Press: Amsterdam, 2013. <https://doi.org/10.1016/C2009-0-64240-9>
11. Aroua, S.; Gabrielle, E.; Ishikawa, T.; Yamakoshi, Y. Well-Defined Amphiphilic  $c_{60}$ -PEG Conjugates: Water-Soluble and Thermoresponsive Materials. *Helvetica Chimica Acta* 2016, 99 (10), 805–813. <https://doi.org/10.1002/hlca.201600171>.
12. Sacchi, A.; Gasparri, A. M.; Monieri, M.; Anderluzzi, G.; Colombo, B.; Gori, A.; Corti, A.; Flavio Curnis. Nanogold Functionalized with Lipamide-IsoDGR: A Simple, Robust and Versatile Nanosystem for Avβ3-Integrin Targeting. *Frontiers in Chemistry* 2021, 9. <https://doi.org/10.3389/fchem.2021.690357>.
13. Sano, K.; Nakajima, T.; Miyazaki, K.; Ohuchi, Y.; Ikegami, T.; Choyke, P. L.; Kobayashi, H. Short PEG-Linkers Improve the Performance of Targeted, Activatable Monoclonal Antibody-Indocyanine Green

- Optical Imaging Probes. *Bioconjugate Chemistry* 2013, 24 (5), 811–816. <https://doi.org/10.1021/bc400050k>.
14. Bishnoi, P.; Saroha, B.; Kumar, S.; Kumar, G.; Bhardwaj, A.; Kumari, M.; Kumar, N. Click Chemistry: An Overview and Recent Updates in the Medicinal Attributes of Click-Derived Heterocycles. *Molecular Diversity* 2025, 29. <https://doi.org/10.1007/s11030-025-11110-z>.
  15. Parcerro-Bouzas, S.; Correa, J.; Jimenez-Lopez, C.; Gonzalez, B. D.; Fernandez-Megia, E. Modular Synthesis of PEG-Dendritic Block Copolymers by Thermal Azide-Alkyne Cycloaddition with Internal Alkynes and Evaluation of Their Self-Assembly for Drug Delivery Applications. *Biomacromolecules* 2024, 25 (5), 2780–2791. <https://doi.org/10.1021/acs.biomac.3c01429>.
  16. Francis, J. N.; Redman, J. S.; Eckert, D. M.; Kay, M. S. Design of a Modular Tetrameric Scaffold for the Synthesis of Membrane-Localized D-Peptide Inhibitors of HIV-1 Entry. *Bioconjugate Chemistry* 2012, 23 (6), 1252–1258. <https://doi.org/10.1021/bc300076f>.
  17. Giese, M.; Davis, P. D.; Woodman, R. H.; Hermanson, G.; Pokora, A.; Vermillion, M. Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates. *Bioconjugate Chemistry* 2021, 32 (10), 2257–2267. <https://doi.org/10.1021/acs.bioconjchem.1c00429>.
  18. Li, L.; Turatti, F.; Crow, D.; Bading, J. R.; Anderson, A.-L.; Poku, E.; Yazaki, P. J.; Williams, L. E.; Tamvakis, D.; Sanders, P.; Leong, D.; Raubitschek, A.; Hudson, P. J.; Colcher, D.; Shively, J. E. Monodispersed DOTA-PEG-Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-To-Blood Ratios Resulting in Improved <sup>64</sup>Cu PET. *Journal of Nuclear Medicine* 2010, 51 (7), 1139–1146. <https://doi.org/10.2967/jnumed.109.074153>.
  19. Li, L.; Crow, D.; Turatti, F.; Bading, J. R.; Anderson, A.-L.; Poku, E.; Yazaki, P. J.; Carmichael, J.; Leong, D.; Wheatcroft, D.; Raubitschek, A. A.; Hudson, P. J.; Colcher, D.; Shively, J. E. Correction to “Site-Specific Conjugation of Monodispersed DOTA-PEGn to Thiolated Diabody Reveals Effect of Increasing Peg Size on Kidney Clearance and Tumor Uptake with Improved 64-Copper PET Imaging.” *Bioconjugate Chemistry* 2011, 22 (6), 1256–1256. <https://doi.org/10.1021/bc2002105>.
  20. Smolensky, E. D.; Park, H.-Y. E.; Berquó, T. S.; Pierre, V. C. Surface Functionalization of Magnetic Iron Oxide Nanoparticles for MRI Applications - Effect of Anchoring Group and Ligand Exchange Protocol. *Contrast Media & Molecular Imaging* 2010, 6, n/a-n/a. <https://doi.org/10.1002/cmml.417>.
  21. Zhu, L.; Xie, J.; Swierczewska, M.; Zhang, F.; Quan, Q.; Ma, Y.; Fang, X.; Kim, K.; Lee, S.; Chen, X. Real-Time Video Imaging of Protease Expression in Vivo. *Theranostics* 2011, 1, 18–27. <https://doi.org/10.7150/thno/v01p0018>.
  22. Jang, H.; Chang, J.-E. Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens. *Pharmaceutics* 2025, 17 (12), 1581. <https://doi.org/10.3390/pharmaceutics1712158>.
  23. Giese, M. W.; Woodman, R. H.; Hermanson, G. T.; Davis, P. D. The Use of Uniform PEG Compounds in the Design of ADCs. *Chemical Linkers in Antibody-Drug Conjugates (ADCs)* 2021, 286–376. <https://doi.org/10.1039/9781839165153-00286>.
  24. Tiberghien, A. C.; Levy, J.-N.; Masterson, L.; Patel, N. V.; Adams, L.; Corbett, S.; Williams, D. R.; Hartley, J.; Howard, P. N. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. *ACS Medicinal Chemistry Letters* 2016, 7 (11), 983–987. <https://doi.org/10.1021/acsmchemlett.6b00062>.
  25. Borbély, A.; Figueras, E.; Martins, A.; Bodero, L.; Raposo Moreira Dias, A.; López Rivas, P.; Pina, A.; Arosio, D.; Gallinari, P.; Frese, M.; Steinkühler, C.; Gennari, C.; Piarulli, U.; Sewald, N. Conjugates of Cryptophycin and RGD or IsoDGR Peptidomimetics for Targeted Drug Delivery. *ChemistryOpen* 2019, 8 (6), 737–742. <https://doi.org/10.1002/open.201900110>.
  26. Quiles, S.; Raisch, K. P.; Sanford, L. L.; Bonner, J. A.; Safavy, A. Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy. *Journal of Medicinal Chemistry* 2009, 53 (2), 586–594. <https://doi.org/10.1021/jm900899g>.
  27. Davis, P.; Crapps, E. THE SELECTIVE and SPECIFIC PREPARATION of DISCRETE PEG COMPOUNDS, July 3, 2019. <https://patentimages.storage.googleapis.com/e8/01/55/3766c06d035142/EP1594440B1.pdf> (accessed 2025-11-26).
  28. Burggraef, M. J.; Oxley, A.; Zaidi, N. A.; Cutillas, P. R.; Gaffney, P. R. J.; Livingston, A. G. Exactly Defined Molecular Weight Poly(Ethylene Glycol) Allows for Facile Identification of PEGylation Sites on Proteins. *Nature Communications* 2024, 15 (1). <https://doi.org/10.1038/s41467-024-54076-6>.
  29. Shi, L.; Zhang, J.; Zhao, M.; Tang, S.; Cheng, X.; Zhang, W.; Li, W.; Liu, X.; Peng, H.; Wang, Q. Effects of Polyethylene Glycol on the Surface of Nanoparticles for Targeted Drug Delivery. *Nanoscale* 2021, 13 (24), 10748–10764. <https://doi.org/10.1039/d1nr02065j>.
  30. Allen, T. M.; Cullis, P. R. Liposomal Drug Delivery Systems: From Concept to Clinical Applications. *Advanced Drug Delivery Reviews* 2013, 65 (1), 36–48. <https://doi.org/10.1016/j.addr.2012.09.037>.
  31. Li, C.; Li, T.; Tian, X.; An, W.; Wang, Z.; Han, B.; Tao, H.; Wang, J.; Wang, X. Research Progress on the PEGylation of Therapeutic Proteins and Peptides (TPPs). *Frontiers in Pharmacology* 2024, 15. <https://doi.org/10.3389/fphar.2024.1353626>.
  32. Ding, H.; Carlton, M. M.; Pivoski, S. P.; Milum, K.; Kumar, K.; Shankaran Kothandaraman; Hinkle, G. H.; Colcher, D.; Brody, R.; Davis, P. D.; Pokora, A.; Phelps, M.; Martin, E. W.; Tweedle, M. F. Site Specific Discrete PEGylation of 124I-Labeled MCC49 Fab' Fragments Improves Tumor MicroPET/CT Imaging in Mice. *Bioconjugate Chemistry* 2013, 24 (11), 1945–1954. <https://doi.org/10.1021/bc400375f>.
  33. Shi, D.; Beasock, D.; Fessler, A. B.; Janos Szebeni; Ljubimova, J. Y.; Afonin, K. A.; Dobrovolskaia, M. A. To PEGylate or Not to PEGylate: Immunological Properties of Nanomedicine's Most Popular Component, Polyethylene Glycol and Its Alternatives. *Advanced Drug Delivery Reviews* 2021, 180, 114079–114079. <https://doi.org/10.1016/j.addr.2021.114079>.
  34. Li, X.; Li, J.; Wei, J.; Du, W.; Su, C.; Shen, X.; Zhao, A.; Xu, M. Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives. *MedComm* 2025, 6 (10). <https://doi.org/10.1002/mco2.70414>.
  35. Chen, B.-M.; Cheng, T.-L.; Roffler, S. R. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. *ACS Nano* 2021, 15 (9), 14022–14048. <https://doi.org/10.1021/acsnano.1c05922>.
  36. Yi Wen Kong; Dreaden, E. C. PEG: Will It Come back to You? Polyethylene Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives. *Frontiers in Bioengineering and Biotechnology* 2022, 10. <https://doi.org/10.3389/fbioe.2022.879988>.



To place an order or receive technical assistance:  
[SigmaAldrich.com/support](https://www.sigmaaldrich.com/support)



For local contact information:  
[SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices)

MilliporeSigma  
400 Summit Drive  
Burlington, MA 01803

[SigmaAldrich.com](https://www.sigmaaldrich.com)

We have built a unique collection of life science brands with unrivalled experience in supporting your scientific advancements.

**Millipore® Sigma-Aldrich® Supelco® Milli-Q® SAFC® BioReliance®**

© 2026 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, BioReliance, Millipore, Milli-Q, SAFC, Sigma-Aldrich, and Supelco are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

MS\_TN15276EN Ver. 1.0 69475 03/2026

